ClinicalTrials.gg
Active, not recruitingNCT07064486Updated Oct 13, 2026

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

A Phase 3 interventional study of BGM0504 and BGM0504 in Type 2 Diabetes (T2DM), sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Active, not recruiting at 4 sites in Indonesia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.

Enrollment
16th of 52
152 · median 85
Started
2025
with 6 others
Phase 3
9 of 66
1 open now
Registered
49th of 66
by date

Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 16th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 9 in phase 3, and was the 49th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, or all of them as a file.
02

Study summary

This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes

03

Conditions studied

  • Type 2 Diabetes (T2DM)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ○ Have been diagnosed with type 2 diabetes mellitus (T2DM);

    • Be on stable treatment with unchanged dose of metformin ≥1500 mg/day or \<1500 mg/day but ≥1000 mg/day (the maximum tolerated dose) for at least 8 weeks prior to screening
    • Have a ≥23 kilograms per meter squared (kg/m²) at screening;
    • Be of stable weight (± 5%) for at least 3 months before screening;
    • Have between ≥7.5% and ≤11.0% at screening

Exclusion criteria

Exclusion Criteria:

  • ○ Previous diagnosis of type 1 diabetes, special type diabetes;

    • Have suffered the within the past 5 years (except cured basal cell carcinoma of the skin, cervical carcinoma in situ), or being evaluated for an underlying malignancy;
    • Have the acute or chronic pancreatitis;
    • Known to be allergic to 3 or more kinds of foods or medications, or allergic to GLP-1 agonist or metformin, or have a severe allergic disease (asthma, urticaria, eczematous dermatitis, etc.) at screening;
    • Have a serious mental illness or speech impediment and be unable to fully understand the study;
    • Suspected or confirmed history of alcohol or drug abuse;
    • Have had a history of ≥2 severe hypoglycemic episodes in the past 1 year;
    • Other conditions that may impact the assessment of products, as determined by the Investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    5 mg BGM0504

    5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

    Drug: BGM0504

  • Experimental
    10 mg BGM0504

    10 mg BGM0504 administered SC once a week.

    Drug: BGM0504

  • Active comparator
    1 mg Semaglutide

    1 mg semaglutide administered SC once a week

    Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in HbA1c after 24 weeks of treatment.

    Time frame: Week 0 to Week 24

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in HbA1c after 12 weeks of treatment.

    Time frame: Week 0 to Week 12

  2. Change From Baseline in Body Weight

    Change from baseline in body weight after 24 weeks of treatment.

    Time frame: Week 0 to Week 24

  3. Percentage of Participants With HbA1c Target Value of <7%

    Percentage of Participants With HbA1c Target Value of \<7% after 24 weeks of treatment.

    Time frame: Week 0 to Week 24

  4. Percentage of Participants With HbA1c Target Value of <5.7%

    Percentage of Participants With HbA1c Target Value of \<5.7%after 24 weeks of treatment.

    Time frame: Week 0 to Week 24

  5. Change From Baseline in Fasting Serum Glucose

    Change from baseline in FPG after 24 weeks of treatment.

    Time frame: Week 0 to Week 24

07

Study locations

4 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 21 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2026 → Apr 2027 and completion Jul 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 14, 2025
StartActual
Jul 4, 2025
Primary completionEst.
Apr 30, 2027was Jul 2026
CompletionEst.
Apr 30, 2027was Jul 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Primary completion
Jul 31, 2026→Apr 30, 2027
Oct 13, 2026
Study completion
Jul 31, 2026→Apr 30, 2027
Oct 13, 2026
Enrollment
477 (estimated)→152 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 31, 2026→Apr 30, 2027
    Study completion Jul 31, 2026→Apr 30, 2027
    Enrollment 477 (estimated)→152 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07064486
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jul 4, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion